165 related articles for article (PubMed ID: 31975354)
21. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
[TBL] [Abstract][Full Text] [Related]
22. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
[TBL] [Abstract][Full Text] [Related]
23. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
[TBL] [Abstract][Full Text] [Related]
24. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
25. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Spyropoulos AC; Goldin M; Ageno W; Albers GW; Elliott CG; Hiatt WR; Halperin JL; Maynard G; Steg PG; Weitz JI; Spiro TE; Lu W; Marsigliano J; Raskob GE; Barnathan ES
TH Open; 2022 Jul; 6(3):e177-e183. PubMed ID: 36046208
[No Abstract] [Full Text] [Related]
27. Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
Yusen RD; Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Chen M; Deslandes B; Turpie AG
Thromb Haemost; 2013 Dec; 110(6):1152-63. PubMed ID: 24085227
[TBL] [Abstract][Full Text] [Related]
28. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
29. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
31. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
32. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
33. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.
Bauersachs RM; Lensing AW; Prins MH; Kubitza D; Pap ÁF; Decousus H; Beyer-Westendorf J; Prandoni P
Thromb J; 2014; 12():25. PubMed ID: 25750589
[TBL] [Abstract][Full Text] [Related]
34. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
36. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
37. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
Miller KM; Brenner MJ
Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
[TBL] [Abstract][Full Text] [Related]
38. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
39. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
Jamil A; Jamil U; Singh K; Khan F; Chi G
Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
[TBL] [Abstract][Full Text] [Related]
40. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
Liew AY; Piran S; Eikelboom JW; Douketis JD
J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
